On the Record · United Therapeutics

United Therapeutics acquisitions, on the record

The businesses United Therapeutics bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
Miromatrix Medical Inc. Word for word“On December 13, 2023, we completed the transactions contemplated by the Merger Agreement and Miromatrix became a wholly-owned subsidiary of United Therapeutics.” 10-K for 2023	acquisition	On December 13, 2023, we completed the transactions contemplated by the Merger Agreement and Miromatrix became a wholly-owned subsidiary of United Therapeutics.	—
IVIVA Medical, Inc. Word for word“In October 2023, we acquired all of the outstanding equity of IVIVA, an early-stage company focused on developing manufactured kidney products, in exchange for an upfront cash payment of approximately $ 50.0 million.” 10-K for 2023	acquisition	In October 2023	approximately $ 50.0 million
Miromatrix Medical Inc. (Miromatrix) Word for word“Regenerative Medicine, Bio-Artificial Organ Alternatives, and 3D Bioprinting of Organ Alternatives • Miromatrix . In December 2023, we acquired Miromatrix Medical Inc. (Miromatrix), a company based in Minnesota focused on the development of new technologies for generating manufactured kidneys and liver alternatives composed of human primary cells.” 10-K for 2024	acquisition	In December 2023, we acquired Miromatrix Medical Inc. (Miromatrix)	—
IVIVA Medical, Inc. (IVIVA) Word for word“In October 2023, we acquired all the outstanding equity of IVIVA, an early-stage company focused on developing manufactured kidney products, in exchange for an upfront cash payment of approximately $ 50.0 million.” 10-K for 2024	acquisition	—	approximately $ 50.0 million
Miromatrix Word for word“Pursuant to the terms of the Merger Agreement, we paid former Miromatrix shareholders $ 3.25 per share in cash at closing, representing cash consideration paid to former Miromatrix shareholders of $ 89.1 million.” 10-K for 2024	acquisition	—	$ 89.1 million

As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year ended	Cash paid for acquisitions (net of cash acquired)
2016-12-31	$5.2 million
2018-12-31	$124.1 million
2019-12-31	$0
2020-12-31	$0
2021-12-31	$0
2022-12-31	$0
2023-12-31	$89.2 million
2024-12-31	$0
2025-12-31	$0

Deal filings since 2016

2026-09-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2026-03-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-08-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-04-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2024-03-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2024-03-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-03-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-04-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-10-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-12-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-06-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-01-25 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2018-11-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-06-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-05-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-01-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-12-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-05-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-01-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-04-28 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-02-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement

Read from United Therapeutics’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-25. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.